ABHD5 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human Huh-7 hepatocellular carcinoma line, engineered for loss of ABHD5 (alpha/beta-hydrolase domain-containing protein 5, also known as CGI-58) function. This gene-edited pool provides a versatile in vitro model to investigate lipid droplet biology and hepatic lipid metabolism, preserving the cellular heterogeneity typical of polyclonal knockout cultures.
Established from a well-differentiated human hepatocellular carcinoma, Huh-7 cells are adherent epithelial cells that retain key hepatocyte characteristics, making them a standard model for liver cancer and hepatitis C virus studies. These cells naturally accumulate lipid droplets and express the molecular machinery for lipolysis, providing a physiologically relevant context for dissecting ABHD5-dependent lipid regulation.
ABHD5 functions as a critical co-activator of adipose triglyceride lipase (ATGL/PNPLA2), the rate-limiting enzyme for triglyceride hydrolysis. Under lipolytic stimulation, catecholamine signaling through PKA phosphorylates perilipin 1, releasing ABHD5 from the lipid droplet surface to bind and activate ATGL. The ATGL?CABHD5 complex hydrolyzes triglycerides into diacylglycerols and free fatty acids, with further processing by hormone-sensitive lipase and monoacylglycerol lipase. ABHD5 thus integrates upstream cues??perilipin 1, PKA, PPAR?? agonists??with downstream free fatty acid release and transcriptional regulation via PPAR?? target genes.
In Huh-7 cells, ABHD5 disruption impairs ATGL activation, causing defective triglyceride catabolism, lipid droplet accumulation, and a steatosis-like phenotype. This mimics pathological features of non-alcoholic fatty liver disease, obesity, and Chanarin-Dorfman syndrome, a lipid storage disorder linked to ABHD5 mutations. The polyclonal knockout cells thus offer a tractable system to explore hepatic lipid dysregulation and its links to insulin resistance and cancer metabolism.
These cells enable mechanistic studies of lipolysis, hepatic steatosis modeling, and drug screening for lipid disorders. They are compatible with Oil Red O and BODIPY staining for lipid droplets, triglyceride quantification, western blotting, RT-qPCR, and metabolic flux analysis, supporting investigations into ABHD5?CATGL?Cperilipin interactions and PPAR?? signaling in liver cancer. For additional technical information or custom gene-edited cell solutions, please contact Ascent Research.
